CompletedNCT04248062
Patient and Observer Reported Outcome Measurements in Inborn Errors of Metabolism
Studying Ornithine transcarbamylase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Children's Hospital, Zurich
- Principal Investigator
- Martina HuemerUniversity Children's Hospital, Zurich
- Intervention
- Survey(other)
- Enrollment
- 69 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2020
Study locations (1)
- University Children's Hospital Zurich, Zurich, Switzerland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04248062 on ClinicalTrials.govOther trials for Ornithine transcarbamylase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06805695Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)iECURE, Inc.
- RECRUITINGPHASE2NCT06488313A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCDArcturus Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT06255782An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC DeficiencyiECURE, Inc.
- RECRUITINGPHASE1, PHASE2NCT05092685Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEnUniversity College, London
- ACTIVE NOT RECRUITINGPHASE3NCT05345171Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) DeficiencyUltragenyx Pharmaceutical Inc
- RECRUITINGNCT04908319Hepatic Histopathology in Urea Cycle DisordersBaylor College of Medicine
- ACTIVE NOT RECRUITINGNCT04612764Liver Disease in Urea Cycle DisordersBaylor College of Medicine
- ACTIVE NOT RECRUITINGNCT03636438Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC DeficiencyUltragenyx Pharmaceutical Inc